RxDoctor Payments Data

Azure Makadzange, MD

Infectious Disease · Stanford, CANPI 1841440716

Payments from drug & device makers

$240,208in general payments, 2019–2025

Across 8 payments — averaging $30,026 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$240K
  • Gilead$124

What the payments were for

  • Food & beverage$225100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck6$240,084
Gilead2$124

How this compares

$240,208 in reported general payments places this provider in the 90th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$9,742
Medicare patients
33
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →